Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Peripheral blood non-canonical small non-coding RNAs as novel biomarkers in lung cancer and pulmonary tuberculosis (validation cohort)

ABSTRACT: Peripheral blood non-canonical small non-coding RNAs as novel biomarkers in lung cancer and pulmonary tuberculosis (validation cohort)

PROVIDER: PRJNA625982 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Peripheral blood non-canonical small non-coding RNAs as novel biomarkers in lung cancer and pulmonary tuberculosis (validation cohort)

Project description:One unmet challenge in current lung cancer diagnosis is to accurately differentiate lung cancer patients from those with other lung diseases with similar clinical symptoms and radiological features. Previous studies have reported cases of misdiagnosis for patients with lung cancer mimicking pulmonary tuberculosis (TB) or for TB patients with multiple lung nodules mimicking lung cancer progression, which is concerning for clinical practice in TB-endemic countries/regions. Here, we develop a molecular signature composed of non-canonical small non-coding RNAs in human peripheral blood mononuclear cells (PBMCs), including tRNA-derived small RNAs (tsRNAs), rRNA-derived small RNAs (rsRNAs), and YRNA-derived small RNAs (ysRNAs). This signature consists of i) the tsRNAs derived from tRNA-Ala, tRNA-Asn, tRNA-Leu, tRNA-Lys, and tRNA-Tyr that are upregulated in the lung cancer patients relative to the healthy controls and patients with pulmonary TB, ii) the rsRNAs derived from rRNA-5S that are upregulated in the lung cancer patients but downregulated in TB patients relative to the controls, and iii) the ysRNAs originating from YRNA-RNY1 that are downregulated in the lung cancer patients but upregulated in the TB patients compared with the controls. This diagnostic signature discriminates between healthy controls, lung cancer patients, and pulmonary TB subjects with high accuracy in both the discovery and validation cohorts. We conclude that the PBMC tsRNAs, rsRNAs, and ysRNAs are informative for both screening for and discriminating between lung cancer and pulmonary TB.

2020-11-16 | GSE148862 | GEO

Tuberculosis biomarker validation cohort

Project description:Tuberculosis biomarker validation cohort

| PRJNA616117 | ENA

Peripheral blood non-canonical small non-coding RNAs as novel biomarkers in lung cancer and pulmonary tuberculosis (discovery cohort)

Project description:Peripheral blood non-canonical small non-coding RNAs as novel biomarkers in lung cancer and pulmonary tuberculosis (discovery cohort)

| PRJNA625983 | ENA

Peripheral blood non-canonical small non-coding RNAs as novel biomarkers in lung cancer and pulmonary tuberculosis (discovery cohort)

2020-11-16 | GSE148861 | GEO

Discovery and validation of urinary molecular signature of early sepsis (validation cohort)

Project description:Discovery and validation of urinary molecular signature of early sepsis (validation cohort)

| PRJNA439295 | ENA

Urine miRNA transcriptome of prostate cancer patients [Validation cohort]

Project description:Intra-individual stability of the urine miRNA transcriptome was examined by investigating longitudinal changes over time in a cohort of patients with localized prostate cancer. Using training and validation cohorts, urinary miRNA biomarkers are characterized and validated their utility to identify aggressive prostate cancer.

2019-10-24 | GSE104430 | GEO

Urine miRNA transcriptome of prostate cancer patients [Validation cohort]

Project description:Urine miRNA transcriptome of prostate cancer patients [Validation cohort]

| PRJNA412692 | ENA

Internal validation cohort of breast cancers for development of ClinicoMolecular Triad Classification

Project description:In our early study (PMID: 21939527), we have created a ClinicoMolecular Triad Classification (CMTC) to improve prediction and prognostication of breast cancer by using a training cohort contained 161 breast cancer patients (2003 to 2008). Here, a supplemental internal validation cohort contained 340 breast cancer patients was collected (2008 to 2010) for development of the CMTC.

2014-06-19 | GSE45725 | GEO

Host gene expression profiling of fungal (candidemia), bacterial, and viral infection, and non-infectious illness [validation cohort]

Project description:Host gene expression profiling of fungal (candidemia), bacterial, and viral infection, and non-infectious illness [validation cohort]

| PRJNA735656 | ENA